Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COGT
stocks logo

COGT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.511
+467.31%
--
--
-0.488
-6.09%
--
--
-0.502
-5.35%
Estimates Revision
The market is revising No Change the revenue expectations for Cogent Biosciences, Inc. (COGT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 201.23%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.89%
In Past 3 Month
Stock Price
Go Up
up Image
+201.23%
In Past 3 Month
Wall Street analysts forecast COGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COGT is 40.64 USD with a low forecast of 20.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast COGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COGT is 40.64 USD with a low forecast of 20.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 39.310
sliders
Low
20.00
Averages
40.64
High
65.00
Current: 39.310
sliders
Low
20.00
Averages
40.64
High
65.00
H.C. Wainwright
H.C. Wainwright
NULL -> Buy
upgrade
$21 -> $50
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$21 -> $50
2025-11-13
upgrade
NULL -> Buy
Reason
H.C. Wainwright raised the firm's price target on Cogent Biosciences to $50 from $21 and keeps a Buy rating on the shares. The firm believes bezuclastinib plus sunitinib is likely to become the standard-of-care in second-line gastrointestinal stromal tumors based on the PEAK trial results.
Baird
Neutral
maintain
$14 -> $34
2025-11-11
Reason
Baird
Price Target
$14 -> $34
2025-11-11
maintain
Neutral
Reason
Baird raised the firm's price target on Cogent Biosciences to $34 from $14 and keeps a Neutral rating on the shares. The firm updated its model following positive Phase 3 PEAK data for Bezu/Sunitnib combo in 2L GIST.
Wedbush
David Nierengarten
Neutral -> Outperform
upgrade
$13 -> $38
2025-11-10
Reason
Wedbush
David Nierengarten
Price Target
$13 -> $38
2025-11-10
upgrade
Neutral -> Outperform
Reason
Wedbush analyst David Nierengarten upgraded Cogent Biosciences to Outperform from Neutral with a price target of $38, up from $13.
Wedbush
David Nierengarten
Neutral -> Outperform
upgrade
$13 -> $38
2025-11-10
Reason
Wedbush
David Nierengarten
Price Target
$13 -> $38
2025-11-10
upgrade
Neutral -> Outperform
Reason
As previously reported, Wedbush analyst David Nierengarten upgraded Cogent Biosciences to Outperform from Neutral with a price target of $38, up from $13, based on "better-than-expected" results from the Phase 3 PEAK trial evaluating bezuclastinib plus sunitinib in patients with imatinib-resistant or intolerant gastrointestinal stromal tumors. Based on the data, the firm believes the combo is "poised to become standard of care" in second-line GIST, with potential utility in earlier and later lines, the analyst tells investors.
Stifel
Hold
to
Buy
upgrade
$16 -> $40
2025-11-10
Reason
Stifel
Price Target
$16 -> $40
2025-11-10
upgrade
Hold
to
Buy
Reason
Stifel upgraded Cogent Biosciences to Buy from Hold with a price target of $40, up from $16.
Leerink
Andrew Berens
Outperform
upgrade
$18 -> $50
2025-11-10
Reason
Leerink
Andrew Berens
Price Target
$18 -> $50
2025-11-10
upgrade
Outperform
Reason
Leerink analyst Andrew Berens raised the firm's price target on Cogent Biosciences to $50 from $18 and keeps an Outperform rating on the shares after the company announced topline results from the Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib versus sunitinib monotherapy in patients with gastrointerstinal stromal tumors after progression on first-line therapy imatinib. The firm calls the results obtained in the second-line "the first positive trial in this disease in over a decade" and sees the data "offering unprecedented efficacy to date" and setting a new standard of care in this disease, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cogent Biosciences Inc (COGT.O) is -19.70, compared to its 5-year average forward P/E of -4.75. For a more detailed relative valuation and DCF analysis to assess Cogent Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.75
Current PE
-19.70
Overvalued PE
-2.53
Undervalued PE
-6.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.97
Undervalued EV/EBITDA
-5.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
32639.48
Current PS
0.00
Overvalued PS
226229.59
Undervalued PS
-160950.63
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 7420.79% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2828.69% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 7420.79% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

COGT News & Events

Events Timeline

(ET)
2025-11-12
06:20:01
Cogent Biosciences Sets Secondary Offering of 9.68 Million Shares at $31.00 Each
select
2025-11-10 (ET)
2025-11-10
16:06:52
Cogent Reveals $200M in Convertible Senior Notes and $200M in Common Stock Offerings
select
2025-11-10
12:01:29
Cogent Biosciences Sees 135.0% Surge
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-28NASDAQ.COM
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26

  • Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.

  • Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.

  • Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.

  • Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.

[object Object]
Preview
9.0
11-13Yahoo Finance
Cogent Biosciences (COGT) Soars 144.5% Following Phase 3 Success of Bezuclastinib and $500M Capital Raise: Has the Bullish Outlook Shifted?

  • Positive Clinical Results: Cogent Biosciences reported promising Phase 3 results for bezuclastinib combined with sunitinib in treating imatinib-resistant gastrointestinal stromal tumors, significantly improving median progression-free survival compared to standard therapy.

  • Capital Raise for Growth: Following the successful trial, the company raised US$300 million in equity and US$200 million through convertible senior notes to expedite the regulatory and commercial process for bezuclastinib.

  • Investment Risks and Opportunities: While the clinical success reduces regulatory uncertainty, Cogent faces challenges such as ongoing operational losses, potential dilution for shareholders, and the need to effectively manage commercialization and competition.

  • Valuation Concerns: Current fair value estimates for Cogent Biosciences suggest it may be overvalued, with investor opinions varying widely, emphasizing the importance of thorough analysis before making investment decisions.

[object Object]
Preview
8.5
11-12SeekingAlpha
Cogent Biosciences Sets Pricing for Equity Offering and 1.625% Convertible Senior Notes

  • Equity and Convertible Notes Offering: Cogent Biosciences has priced its public offering of approximately 9.68 million shares at $31.00 each and $200 million in convertible senior notes due 2031, with net proceeds expected to be around $475.3 million.

  • Use of Proceeds: The funds will be utilized to repay $50 million in existing loans, support development and regulatory activities for bezuclastinib and other candidates, and cover working capital and general corporate purposes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cogent Biosciences Inc (COGT) stock price today?

The current price of COGT is 39.31 USD — it has increased 0.38 % in the last trading day.

arrow icon

What is Cogent Biosciences Inc (COGT)'s business?

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

arrow icon

What is the price predicton of COGT Stock?

Wall Street analysts forecast COGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COGT is 40.64 USD with a low forecast of 20.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cogent Biosciences Inc (COGT)'s revenue for the last quarter?

Cogent Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Cogent Biosciences Inc (COGT)'s earnings per share (EPS) for the last quarter?

Cogent Biosciences Inc. EPS for the last quarter amounts to -0.59 USD, decreased -7.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cogent Biosciences Inc (COGT)'s fundamentals?

The market is revising No Change the revenue expectations for Cogent Biosciences, Inc. (COGT) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 201.23%.
arrow icon

How many employees does Cogent Biosciences Inc (COGT). have?

Cogent Biosciences Inc (COGT) has 205 emplpoyees as of December 05 2025.

arrow icon

What is Cogent Biosciences Inc (COGT) market cap?

Today COGT has the market capitalization of 6.03B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free